Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

Results 1-4 of 4 (Search time: 0.005 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2014D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trialChristersson, C.; Wallentin, L.; Andersson, U.; Alexander, J.; Ansell, J.; De Caterina, R.; Gersh, B.; Granger, C.; Hanna, M.; Horowitz, J.; Huber, K.; Husted, S.; Hylek, E.; Lopes, R.; Siegbahn, A.
2014Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trialWallentin, L.; Hijazi, Z.; Andersson, U.; Alexander, J.; De Caterina, R.; Hanna, M.; Horowitz, J.; Hylek, E.; Lopes, R.; ├ůsberg, S.; Granger, C.; Siegbahn, A.
2014Response to letter regarding article, "efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation"Wallentin, L.; Lopes, R.; Hanna, M.; Thomas, L.; Hellkamp, A.; Nepal, S.; Hylek, E.; Al-Khatib, S.; Alexander, J.; Alings, M.; Amerena, J.; Ansell, J.; Aylward, P.; Bartunek, J.; Commerford, P.; De Caterina, R.; Erol, C.; Harjola, V.; Held, C.; Horowitz, J.; et al.
2014High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarinHijazi, Z.; Wallentin, L.; Siegbahn, A.; Andersson, U.; Alexander, J.; Atar, D.; Gersh, B.; Hanna, M.; Harjola, V.; Horowitz, J.; Husted, S.; Hylek, E.; Lopes, R.; McMurray, J.; Granger, C.